Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast
Globe Newswire

MELBOURNE, Australia and NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended December 31, 2015 and provide a corporate update beginning at 5:00 pm Eastern Time on Tuesday, February 16, 2016 / 09:00 am Australian Eastern Daylight Time on Wednesday, February 17, 2016.  

To access the call, dial 877-456-0438 (toll-free US), 1800-005-989 (toll-free Australia) or 262-558-6163 (outside of the US). The passcode is 49888069. The conference call will be accompanied by a slide presentation. Please log in approximately 10 minutes prior to the scheduled start time.  The live webcast can be accessed by clicking here.

The archived webcast will be available in the Events and Presentations section of the Investor page on the Mesoblast website, which can be accessed by clicking here.

About Mesoblast

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.

For further information, please contact:
Michael Schuster
Head, Investor Relations
Mesoblast Limited
T:  212-880-2060 
E: michael.schuster@mesoblast.com
Julie Meldrum
Global Head, Corporate Communications
Mesoblast Limited
T: +61 3 9639 6036  
E: julie.meldrum@mesoblast.com

Primary Logo

 Top of page